Eli Lilly Agrees to $3.8 Billion Acquisition of AtaiBeckley in Psychedelic Push
The deal marks a significant expansion of the pharmaceutical giant’s portfolio, leveraging financial gains from its weight-loss drugs to enter the rapidly evolving psychedelic therapy market.
Eli Lilly has announced an agreement to acquire psychedelic drugmaker AtaiBeckley for an upfront payment of $2.8 billion, with the potential for up to $1 billion in additional contingent payments, bringing the total deal value to $3.8 billion. The acquisition grants the pharmaceutical giant access to BPL-003, a psychedelic-based nasal spray that studies indicate can reduce symptoms of treatment-resistant depression with a single dose.
The transaction represents a strategic expansion of Eli Lilly’s neuroscience portfolio, building on its historical presence in the sector which includes the introduction of the antidepressant Prozac in the late 1980s and the approval of its first Alzheimer’s disease treatment in 2024. This move follows a series of acquisitions completed in May aimed at bolstering the company’s infectious disease capabilities, funded by the financial growth of its blockbuster weight-loss and diabetes drugs, Mounjaro and Zepbound.
Christian Angermayer, founder and chairman of AtaiBeckley, stated that the deal validates the mainstream acceptance of psychedelics. In a post on X, Angermayer noted that the agreement demonstrates that the sector has achieved a level of awareness and legitimacy that many previously considered impossible.
The acquisition occurs shortly after the White House directed the Food and Drug Administration in April to fast-track research and approvals for psychedelics. The deal is the latest evidence that major pharmaceutical companies are transitioning from speculative interest to substantial investment in the space. Competitors are already active, with AbbVie acquiring Gilgamesh Pharmaceuticals’ lead drug, Bretisilocin, for up to $1.2 billion in October, while Johnson & Johnson markets Spravato, a depression drug whose sales have more than doubled since 2023 to reach $1.7 billion.
Analysts estimate that the psychedelic therapy market could generate approximately $7 billion in annual sales by 2032, contingent on further regulatory approvals for various therapies. While the final deal value depends on meeting specific conditions, the agreement underscores the growing confidence of established pharmaceutical firms in the commercial viability of psychedelic-based treatments.
